38 results on '"A. Barletta"'
Search Results
2. 66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
3. EP08.01-088 Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
4. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
5. Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial
6. EP08.01-088 Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
7. Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
8. 192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)
9. 192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)
10. P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
11. P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
12. P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
13. P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
14. P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
15. P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
16. P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
17. Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
18. P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab
19. P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
20. P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab
21. P3.02c-039 Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer
22. P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer
23. MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response
24. P3.02c-054 Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab
25. MA10.11 Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer
26. P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
27. P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
28. P3.02c-039 Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer
29. P3.02c-077 Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab
30. P3.02c-054 Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab
31. P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer
32. P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
33. P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab
34. MA10.11 Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer
35. MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response
36. P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
37. P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab
38. P3.02c-077 Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.